Protalix BioTherapeutics (NYSE:PLX) Downgraded by StockNews.com to Buy

StockNews.com lowered shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a research report released on Tuesday morning.

Separately, HC Wainwright lifted their price target on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday.

Protalix BioTherapeutics Stock Up 0.7 %

Shares of Protalix BioTherapeutics stock opened at $2.69 on Tuesday. Protalix BioTherapeutics has a 52-week low of $0.82 and a 52-week high of $2.76. The company has a 50 day moving average of $2.03 and a 200 day moving average of $1.44. The company has a market capitalization of $198.06 million, a P/E ratio of -20.69 and a beta of 0.75.

Institutional Trading of Protalix BioTherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $35,000. PFG Investments LLC acquired a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at $39,000. Cubist Systematic Strategies LLC acquired a new position in shares of Protalix BioTherapeutics in the 2nd quarter valued at $37,000. GSA Capital Partners LLP increased its holdings in shares of Protalix BioTherapeutics by 8.5% in the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock valued at $444,000 after acquiring an additional 33,969 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Protalix BioTherapeutics in the 3rd quarter valued at $36,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.